CA-ASM-GLOBAL
21.7.2022 15:02:08 CEST | Business Wire | Press release
ASM Global, the world’s leading venue management company and producer of live experiences, has partnered with the Malaysian Ministry of Youth and Sports via Perbadanan Stadium Malaysia (PSM) to enhance existing operations and event activity at the Kuala Lumpur Sports City precinct, the largest sports complex in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005375/en/
The announcement is a further step forward in the Malaysian government’s ambition to see the National Sports Precinct at Bukit Jalil develop a world-class reputation as the host of leading sports, entertainment and community events. It also expands ASM Global’s footprint in Asia with the addition of an iconic sports and events precinct, including the 87,400-seat Malaysia National Stadium.
The Malaysia National Stadium is not only the largest stadium in Asia outside North Korea, it is now the largest stadium in ASM Global’s worldwide collection.
ASM Global brings its vast industry experience in redefining the guest journey, implementing the latest technology, elevating F&B offerings, and the advantage of a regionally based team together with its commercial venue know-how, wide ranging event network and technical capabilities.
ASM Global President and CEO Ron Bension said, “We’re on a robust growth curve in this part of the world. The Kuala Lumpur Sports City precinct is representative of the types of projects we’re championing that significantly enrich the venue benefits and utilize our vast international expertise and best practices.”
Chairman and Chief Executive of ASM Global Asia Pacific and Gulf Region Harvey Lister AM said the group was delighted to be partnering with the management team at the iconic Kuala Lumpur Sports City in a joint endeavor to further establish the precinct as a vibrant community and event hub for the people of Malaysia.
“We firmly believe the Malaysia National Stadium and the Axiata Arena have the potential expressed by the Malaysia Sports Ministry, and we are proud to welcome the local teams and venues into our network of venues and support the precinct in helping deliver more events for the people of Malaysia and the region,” said Lister.
ASM Global will partner with local Malaysian company Sportswork Sdn Bhd in delivering services for Kuala Lumpur Sports City.
Malaysia Sports Minister, Y.B. Dato’ Seri Ahmad Faizal bin Dato’ Azumu, said, “We see this MOU as a great opportunity for PSM and ASM Global to enhance Kuala Lumpur Sports City to a premier destination in the global sports and event industry. Both National Stadium Bukit Jalil and Axiata Arena are iconic properties owned by the Malaysian people, and we owe them a responsibility to ensure these venues make us proud.”
ABOUT ASM GLOBAL
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook , Instagram , LinkedIn and Twitter . asmglobal.com
ASM Global’s expanding family of facilities in the Asia Pacific includes the following venues:
- Entertainment and Sports Arenas: Qudos Bank Arena, Sydney; RAC Arena, Perth; Brisbane Entertainment Centre; Newcastle Entertainment Centre; Aware Super Theatre at ICC Sydney; BCEC Great Hall, Brisbane; Cairns Arena: Bangkok Arena and EM Live Theatre, Bangkok (under development), Coca Cola Arena, Dubai; Kai Tak Indoor Arena, Hong Kong; and Jeddah Arena, Saudi Arabia (under development).
- Live Performance Theatres: Brisbane, Cairns, Darwin, Sydney, Kuala Lumpur and Bahrain.
- Convention and Exhibition Centres: Brisbane, Cairns, Darwin, Newcastle, Sydney, Christchurch, Kuala Lumpur, Shenzhen, Bahrain (under construction) and Jeddah (under development).
- Stadiums: Suncorp Stadium in Brisbane; Kai Tak Sports Park, Hong Kong (under construction); a significant ownership of VenuesLive, the operator of Stadium Australia, Sydney; CommBank Stadium, Parramatta; Optus Stadium, Perth, and service provider to WIN Stadium, Wollongong; McDonald Jones Stadium, Newcastle; Netstrata Jubilee Stadium, Sydney; and Central Coast Stadium, Gosford.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom